GEPATIT B VIRUSINING O'SMA KASALLIKLARI RIVOJLANISHIDAGI ROLI

Authors

  • Gulbahor E. Raxmonova Author
  • Karima Abdurahmonova Author
  • Quvonchbek Xushboqov Author
  • Elmurodov Azizbek Samariddin o’g’li Author

Keywords:

Hepatitis B virus, jigar saratoni, Hepatocellular carcinoma, onkogenez, surunkali gepatit, sirroz, virusli gepatit, karsinogenez, DNK mutatsiyasi, HBV infeksiyasi, malign o‘sma, gepatologiya, onkologiya, vaksinatsiya.

Abstract

Gepatit B virusi (GBV) dunyo bo'ylab surunkali jigar kasalliklarining asosiy sabablaridan biri bo'lib, jigarxujayra karsinomasi (JXK) rivojlanishida hal qiluvchi rol o'ynaydi. Mazkur adabiyotlar tahlili GBV ning onkogen mexanizmlarini qamrab oladi: HBx oqsilining ko'plab signal yo'llariga ta'siri va epigenetik o'zgarishlar, viral DNKning xost genomiga integratsiyasi, immunologik charchash va oksidativ stress.
JSST 2024-yilgi ma'lumotlariga ko'ra, 240 million kishi surunkali GBV infeksiyasi bilan yashaydi va har yili 1,3 million kishi virus bilan bog'liq asoratlardan vafot etmoqda. JXK barcha jigar saraton holatlarining 50–80% ini tashkil etib, GBV bu kasallikning bosh etiologik omili hisoblanadi. Maqolada zamonaviy antiviral terapiya – nukleozid/nukleotid analoglar (entekavir, tenofovir) va pegillangan
interferon – va ularning JXK oldini olishdagi roli muhokama qilinadi. Xulosa qismida GBV bilan bog'liq o'sma kasalliklarining erta tashxisi va davolashda yangi yondashuvlar belgilanadi.

References

[1] World Health Organization. Global Hepatitis Report 2026. WHO,

Geneva, 2026. https://www.who.int/teams/global-hiv-hepatitis-and-stisprogrammes/hepatitis/reports/global-hepatitis-report-2026

[2] World Health Organization. Hepatitis Global Data and Statistics, 2022.

https://www.who.int/data/gho/data/themes/chronic-viral-hepatitis

[3] GBD 2019 Hepatitis B Collaborators. Global, regional, and national

burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of

Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796-829.

doi:10.1016/S2468-1253(22)00124-8

[4] Razavi H et al. Global burden of hepatitis B virus: current status, missed

opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20(9):562-

579. doi:10.1038/s41575-023-00760-9

[5] Wong GLH, Chan HLY. Secondary prevention for hepatocellular

carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues

the same? Hepatol Int. 2020;14(5):693-701. doi:10.1007/s12072-020-10077-3

[6] Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis

C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J. 2018;12:26-32.

doi:10.2174/1874357901812010026

[7] Al-Busafi SA, Alwassief A. Global Perspectives on the Hepatitis B

Vaccination: Challenges, Achievements, and the Road to Elimination by 2030.

Vaccines (Basel). 2024;12(3):288. doi:10.3390/vaccines12030288

[8] Sivasudhan E, Blake N, Lu Z, Meng J, Rong R. Hepatitis B Viral Protein

HBx and the Molecular Mechanisms Modulating the Hallmarks of Hepatocellular

Carcinoma: A Comprehensive Review. Cells. 2022;11(4):741.

doi:10.3390/cells11040741

[9] Guo Y, Feng X, Jiang Y et al. HBV-Induced Immune Imbalance in the

Development of HCC. Front Immunol. 2019;10:2048.

doi:10.3389/fimmu.2019.02048

[10] Yeh TS, Chen CL, Huang SF. HBeAg and its Precursors in the Pathway

to Hepatocellular Carcinoma. Viruses. 2023;15(4):857. doi:10.3390/v15040857

[11] Hassan Z et al. The oncogenic role of hepatitis B virus X gene in

hepatocarcinogenesis: recent updates. Front Oncol. 2024;14:1360655.

doi:10.3389/fonc.2024.1360655

[12] Lefeuvre C, Le Guillou-Guillemette H, Ducancelle A. A Pleiotropic

Role of the Hepatitis B Virus Core Protein in Hepatocarcinogenesis. Int J Mol Sci.

2021;22(24):13651. doi:10.3390/ijms222413651

[13] Yeh SH, Li CL, Lin YY et al. Hepatitis B Virus DNA Integration Drives

Carcinogenesis and Provides a New Biomarker for HBV-related HCC. Cell Mol

Gastroenterol Hepatol. 2023;15(4):921-929. doi:10.1016/j.jcmgh.2023.01.001

[14] Rinaldi L et al. Hepatitis B virus DNA integration as a novel biomarker

of HBV-mediated pathogenetic properties and a barrier to the current strategies for

HBV cure. Front Microbiol. 2022;13:972687. doi:10.3389/fmicb.2022.972687

Published

2026-05-10